BioXcel Therapeutics Inc. (BTAI) is a clinical-phase biopharmaceutical company headquartered in New Haven, Connecticut, specializing in the application of artificial intelligence to revolutionize drug discovery and development, particularly in neuroscience and immuno-oncology. The company is advancing a strong pipeline of innovative therapies that target significant unmet medical needs, emphasizing its commitment to improving patient outcomes. By integrating advanced AI technology with extensive scientific expertise, BioXcel is strategically positioned to drive transformative advances in healthcare, making it an attractive prospect for institutional investors looking to capitalize on growth opportunities within the biopharmaceutical landscape. Show more

Location: 555 LONG WHARF DRIVE, NEW HAVEN, CT, UNITED STATES, 06511, New Haven, CT, 06511, USA | Website: https://www.bioxceltherapeutics.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

34.77M

52 Wk Range

$1.17 - $8.08

Previous Close

$1.62

Open

$1.61

Volume

596,613

Day Range

$1.52 - $1.62

Enterprise Value

108.5M

Cash

37.32M

Avg Qtr Burn

-18.79M

Insider Ownership

4.21%

Institutional Own.

12.59%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IGALMI (dexmedetomidine) (BXCL501) Details Schizophrenia or bipolar I/II disorder-associated agitation	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Acute agitation associated with schizophrenia & bipolar disorder	sNDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Dementia, Alzheimer's disease, Agitation in Alzheimer's Disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL701 + KEYTRUDA Details Neuroendocrine prostate cancer, Castration-resistant prostate cancer	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL701 + KEYTRUDA Details Solid tumor/s, Cancer, Pancreatic cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 + Duloxetine Details Major depressive disorder	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Mental health, Acute stress disorder	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Opioid use disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Mental health, Delirium, Agitation	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.